<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />




<title>anaemia.knit</title>

<script src="site_libs/header-attrs-2.20/header-attrs.js"></script>
<script src="site_libs/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="site_libs/bootstrap-3.3.5/css/flatly.min.css" rel="stylesheet" />
<script src="site_libs/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="site_libs/jqueryui-1.11.4/jquery-ui.min.js"></script>
<link href="site_libs/tocify-1.9.1/jquery.tocify.css" rel="stylesheet" />
<script src="site_libs/tocify-1.9.1/jquery.tocify.js"></script>
<script src="site_libs/navigation-1.1/tabsets.js"></script>
<link href="site_libs/font-awesome-5.1.0/css/all.css" rel="stylesheet" />
<link href="site_libs/font-awesome-5.1.0/css/v4-shims.css" rel="stylesheet" />

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>







<link rel="stylesheet" href="styles.css" type="text/css" />



<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
details > summary > p:only-child {
  display: inline;
}
pre code {
  padding: 0;
}
</style>


<style type="text/css">
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #adb5bd;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script type="text/javascript">
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark the anchor link active (and if it's in a dropdown, also mark that active)
  var dropdown = menuAnchor.closest('li.dropdown');
  if (window.bootstrap) { // Bootstrap 4+
    menuAnchor.addClass('active');
    dropdown.find('> .dropdown-toggle').addClass('active');
  } else { // Bootstrap 3
    menuAnchor.parent().addClass('active');
    dropdown.addClass('active');
  }

  // Navbar adjustments
  var navHeight = $(".navbar").first().height() + 15;
  var style = document.createElement('style');
  var pt = "padding-top: " + navHeight + "px; ";
  var mt = "margin-top: -" + navHeight + "px; ";
  var css = "";
  // offset scroll position for anchor links (for fixed navbar)
  for (var i = 1; i <= 6; i++) {
    css += ".section h" + i + "{ " + pt + mt + "}\n";
  }
  style.innerHTML = "body {" + pt + "padding-bottom: 40px; }\n" + css;
  document.head.appendChild(style);
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before, .tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "\e259";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "\e258";
  font-family: 'Glyphicons Halflings';
  border: none;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->



<style type="text/css">

#TOC {
  margin: 25px 0px 20px 0px;
}
@media (max-width: 768px) {
#TOC {
  position: relative;
  width: 100%;
}
}

@media print {
.toc-content {
  /* see https://github.com/w3c/csswg-drafts/issues/4434 */
  float: right;
}
}

.toc-content {
  padding-left: 30px;
  padding-right: 40px;
}

div.main-container {
  max-width: 1200px;
}

div.tocify {
  width: 20%;
  max-width: 260px;
  max-height: 85%;
}

@media (min-width: 768px) and (max-width: 991px) {
  div.tocify {
    width: 25%;
  }
}

@media (max-width: 767px) {
  div.tocify {
    width: 100%;
    max-width: none;
  }
}

.tocify ul, .tocify li {
  line-height: 20px;
}

.tocify-subheader .tocify-item {
  font-size: 0.90em;
}

.tocify .list-group-item {
  border-radius: 0px;
}

.tocify-subheader {
  display: inline;
}
.tocify-subheader .tocify-item {
  font-size: 0.95em;
}

</style>



</head>

<body>


<div class="container-fluid main-container">


<!-- setup 3col/9col grid for toc_float and main content  -->
<div class="row">
<div class="col-xs-12 col-sm-4 col-md-3">
<div id="TOC" class="tocify">
</div>
</div>

<div class="toc-content col-xs-12 col-sm-8 col-md-9">




<div class="navbar navbar-default  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">Renal Medicine</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    Research
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="./trials.html">Trials</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    GEN
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="./HTN.html">HTN</a>
    </li>
    <li>
      <a href="./CCF.html">CCF</a>
    </li>
    <li>
      <a href="./DKD.html">DKD</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    U&amp;E
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="./acidbase.html">H+ &amp; HCO3</a>
    </li>
    <li>
      <a href="./na.html">Na</a>
    </li>
    <li>
      <a href="./k.html">K</a>
    </li>
    <li>
      <a href="./mg.html">MG</a>
    </li>
    <li>
      <a href="./renalbone.html">Ca2+ &amp; PO4</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    GN
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="./MCD.html">MCD</a>
    </li>
    <li>
      <a href="./ANCA.html">ANCA</a>
    </li>
    <li>
      <a href="./IGAN.html">IGAN</a>
    </li>
    <li>
      <a href="./MPGN_C3G.html">MPGN &amp; C3G</a>
    </li>
    <li>
      <a href="./LUPUS.html">LUPUS</a>
    </li>
    <li>
      <a href="./FSGS.html">FSGS</a>
    </li>
    <li>
      <a href="./TMA.html">TMA</a>
    </li>
    <li>
      <a href="./GBM.html">GBM</a>
    </li>
    <li>
      <a href="./MN.html">MN</a>
    </li>
    <li>
      <a href="./Amyloid.html">Amyloid</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    CKD
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="./project1.html">Checklist</a>
    </li>
    <li>
      <a href="./project1.html">Conservative care</a>
    </li>
    <li>
      <a href="./anaemia.html">Anaemia</a>
    </li>
    <li>
      <a href="./project1.html">Pruritis</a>
    </li>
    <li>
      <a href="./renalbone.html">CKD-MBD</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    TX
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="./project1.html">Cheat sheet</a>
    </li>
    <li>
      <a href="./txnotes.html">Misc Notes</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    RRT
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="./HD.html">HD</a>
    </li>
    <li>
      <a href="./project1.html">Home HD</a>
    </li>
    <li>
      <a href="./project1.html">HD Access</a>
    </li>
    <li>
      <a href="./project1.html">PD</a>
    </li>
    <li>
      <a href="./project1.html">CVVH</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    DRUGS
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="./abx.html">Abx</a>
    </li>
    <li>
      <a href="./aboutme.html">HDU</a>
    </li>
    <li>
      <a href="./project1.html">Flozins</a>
    </li>
    <li>
      <a href="./rituxcyc.html">RITUX &amp; CYC</a>
    </li>
    <li>
      <a href="./Chemotherapy.html">Chemo</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    MISC
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="./biopsy.html">Biopsy</a>
    </li>
    <li>
      <a href="./path.html">PATH</a>
    </li>
    <li>
      <a href="./preg.html">Pregnancy</a>
    </li>
    <li>
      <a href="./project1.html">PEX</a>
    </li>
    <li>
      <a href="./Lymphoproliferative.html">Lymphoproliferative</a>
    </li>
    <li>
      <a href="./covid19.html">SARS-Cov-2</a>
    </li>
    <li>
      <a href="./Tumour_Lysis.html">Tumour Lysis Syndrome</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    EDU
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="./edu.html">Educational Resources</a>
    </li>
  </ul>
</li>
      </ul>
      <ul class="nav navbar-nav navbar-right">
        <li>
  <a href="https:eoindosullivan.com">
    <span class="fas fa-home"></span>
     
  </a>
</li>
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div id="header">




</div>


<div id="anaemia" class="section level1">
<h1>Anaemia</h1>
</div>
<div id="iron" class="section level1">
<h1>Iron</h1>
<ul>
<li>Screen annually in CKD G3, biannually in CKD G4</li>
<li>Investigate - EPO def is dx of exclusion. “possible”” in eGFR
&lt;60, “probable” in &lt;30</li>
</ul>
<div id="iron-studies" class="section level4">
<h4>Iron studies</h4>
<ul>
<li>% HRC if able to process within 6 hours</li>
<li>Reticulocyte Hb count (CHr)</li>
<li>TSATS and ferritin ( if above not available or thalassaemia)</li>
<li>Ferritin &amp; CRP</li>
<li>PTH &amp; TFT ( can contribute to iron def)</li>
<li>Consider - b12/folate/haemolysis/plasma&amp;urine electrophroesis,
hb electrophoresis, LTC &amp; Marrow</li>
<li>Scopes etc</li>
</ul>
</div>
<div id="iron-repletion" class="section level4">
<h4>Iron repletion</h4>
<ul>
<li>%HRC &lt;6% / CHr &gt;29 pg / ferritin and TSAT (&gt;100 microgram/L
and &gt;20%).</li>
<li>Oral iron usually ok for CKD, ~PD. IV for HD.</li>
<li>If not in centre, high dose low frequency is good</li>
</ul>
</div>
<div id="oral-iron-is-viable-in-mild-ckd" class="section level4">
<h4>Oral iron is viable in mild CKD</h4>
<ul>
<li>Interestingly alternate day dosing is higher in absorbtion to daily
dosing per <a
href="https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30182-5/fulltext">Lancet
haematology</a></li>
<li>measuring the isotopic label abundance in erythrocytes 14 days after
administration, and serum hepcidin.</li>
<li>iron deficient women who were not anaemia</li>
<li>shock, horror, no CKD included</li>
<li>hard to generalise this observation to our patients but it is
intriguing imo</li>
</ul>
</div>
<div id="iron-therapy" class="section level4">
<h4>Iron Therapy</h4>
<ul>
<li><p>In HD proactive high-dose IV iron sucrose (venofer) 400 mg every
month (or equivalent) should be given unless ferritin &gt; 700 μg/L or
TSAT&gt;40% ( PIVITOL)</p></li>
<li><p>Avoid in infection, probably</p></li>
<li><p>Monitor quarterly</p></li>
<li><p>Hb Targets: 100-120</p></li>
<li><p>Caution in malignancy</p></li>
<li><p>ferrinject (Ferrous carboxymaltose) has reports of hypophos
fairly consistantly in trials</p></li>
<li><p><strong>Limits</strong> Feritin =&lt; 800. Review iron therapy
when hits 500.</p></li>
</ul>
<p>In Edinburgh use iron as ferric derisomaltose (Diafer) ~100mg
weekly/monthly etc during HD. This is low dose :(</p>
</div>
<div id="pivotal" class="section level2">
<h2>PIVOTAL</h2>
<br>
<style>
div.blue { background-color:#e6f0ff; border-radius: 5px; padding: 20px;}
</style>
<div class="blue">
<p><a
href="https://www.nejm.org/doi/full/10.1056/nejmoa1810742">PIVOTAL</a></p>
<ul>
<li>High dose IV iron vs low dose</li>
<li>High dose non inferior for compositive CV | death endpoint</li>
<li>Less CV composite events in high dose hazard ratio, 0.80; 95% CI,
0.64 to 1.00</li>
<li>Less Blood transfusions</li>
<li>Same infections</li>
</ul>
</div>
<p><br></p>
</div>
</div>
<div id="esa" class="section level1">
<h1>ESA</h1>
<ul>
<li>Caution htn - 175/95 as arbitrary cut offs</li>
<li>Neorecoromon is 150 units/kg body weight/week. This is usually
administered as 3 divided doses (but can be given as a single weekly
dose), given intravenously during haemodialysis. 70kg man gets 3500
units each session (10,500/3)</li>
<li>Adjust in 25-50% increments</li>
</ul>
<div id="hb-targets" class="section level2">
<h2>HB Targets</h2>
</div>
<div id="normal-heamatocrit-trial" class="section level2">
<h2>NORMAL HEAMATOCRIT TRIAL</h2>
<br>
<style>
div.blue { background-color:#e6f0ff; border-radius: 5px; padding: 20px;}
</style>
<div class="blue">
<p><a href="https://pubmed.ncbi.nlm.nih.gov/9718377/">NHT</a></p>
<ul>
<li>Intervention: EPO-a :: target Hb 13-15, vs rescue Hb 9-11 on HD with
CVD</li>
<li>Endpoint: Death &amp; non-fatal MI</li>
<li>Results: N=1265 | risk ratio for the normal-hematocrit group as
compared with the low-hematocrit group, 1.3; 95 percent confidence
interval, 0.9 to 1.9</li>
<li>Stopped early due to safety concerns</li>
<li>mortality rates decreased with increasing hematocrit values in both
groups.</li>
<li>The patients in the normal-hematocrit group had a decline in the
adequacy of dialysis and received intravenous iron dextran more often
than those in the low-hematocrit group.</li>
</ul>
</div>
<p><br></p>
</div>
<div id="choir" class="section level2">
<h2>CHOIR</h2>
<br>
<style>
div.blue { background-color:#e6f0ff; border-radius: 5px; padding: 20px;}
</style>
<div class="blue">
<p><a href="https://pubmed.ncbi.nlm.nih.gov/17108343/">CHOIR</a></p>
<ul>
<li><p>Intervention: EPO-a :: target Hb 13.5 vs 11.3 in CKD eGFR
&gt;15</p></li>
<li><p>Endpoint: CV events including death, MI, hospitalizations for
CHF, and stroke</p></li>
<li><p>Results: N=1432 | Composite of death, MI, hospitalization for
CHF, or stroke 17.5% vs. 13.5% (HR 1.34; 95% CI 1.03-1.74; P=0.03) |
More SAE 54.8% vs. 48.5% (P=0.02), CHF 11.2% vs. 7.4% (P=0.02) although
less MI 1.5 vs. 2.8% (P=0.09)</p></li>
<li><p>Even though the study population was randomized, the high Hgb
group had more comorbid conditions, including a greater percentage of
HTN, history of CABG, and severe CHF.</p></li>
<li><p>The high-Hgb group was not able to reach the target Hgb level
despite higher doses of erythropoietin.</p></li>
<li><p>The trial was open-label, not double-blinded.</p></li>
</ul>
</div>
<p><br></p>
</div>
<div id="treat" class="section level2">
<h2>TREAT</h2>
<br>
<style>
div.blue { background-color:#e6f0ff; border-radius: 5px; padding: 20px;}
</style>
<div class="blue">
<p><a href="https://pubmed.ncbi.nlm.nih.gov/19880844/">TREAT</a></p>
<ul>
<li><p>Intervention: Darbo :: target Hb &gt;10 vs rescue ESA if &lt;9 in
CKD eGFR &gt;20, DM2,Hb&lt;11, TSATS &gt;15%</p></li>
<li><p>Endpoint: death or CV events and death or ESRD, stroke</p></li>
<li><p>Results: N=4038 | Death or CV: 31.4% vs. 29.7% (HR 1.05; 95% CI,
0.94 to 1.17; P=0.41), Death or ESRD 32.4% vs. 30.5% (HR 1.06; 95% CI,
0.95 to 1.19; P=0.29)</p></li>
<li><p>5% vs. 2.5% (HR 1.92; 95% CI 1.38-2.68; P&lt;0.001; NNH
40)</p></li>
<li><p>Less fatigue though!!</p></li>
<li><p>Did not target different hemoglobin levels for different
sexes</p></li>
<li><p>Incomplete details pertaining to stroke</p></li>
<li><p>Unclear effect of iron administration in placebo group</p></li>
</ul>
</div>
<p><br></p>
</div>
<div id="create" class="section level2">
<h2>CREATE</h2>
<br>
<style>
div.blue { background-color:#e6f0ff; border-radius: 5px; padding: 20px;}
</style>
<div class="blue">
<p><a href="https://pubmed.ncbi.nlm.nih.gov/17108342/">CREATE</a></p>
<ul>
<li>Intervention: EPO-beta :: target Hb &gt;13-15, vs rescue Hb
10.5-11.5 in CKD eGFR 15-30</li>
<li>Endpoint: composite of eight cardiovascular events; secondary end
points included left ventricular mass index, quality-of-life scores, and
the progression of chronic kidney disease.</li>
<li>Results: N=603 | OVer 3 years (58 events in group 1 vs. 47 events in
group 2; hazard ratio, 0.78; 95% confidence interval, 0.53 to 1.14;
P=0.20).</li>
<li>Dialysis was required in more patients in group 1 than in group 2
(127 vs. 111, P=0.03)</li>
<li>But slightly confusingly mean eGFR was the same ~24</li>
<li>General health and physical function improved significantly (P=0.003
and P&lt;0.001, respectively, in group 1, as compared with group
2).</li>
<li>SAE similar but more HTN in higher hb</li>
</ul>
</div>
<p><br></p>
<div id="resistance-to-esa-therapy" class="section level4">
<h4>Resistance to ESA therapy</h4>
<p>Failure to reach the target Hb level despite SC epoetin dose &gt;300
IU/kg/week (450 IU/kg/week IV epoetin), or darbepoetin dose &gt;1.5
microgram/kg/week. ( 70kg man = 7000 units/session)</p>
<p>Hyporesponsive patients who are iron replete should be screened
clinically and by investigations for other common causes of anaemia.</p>
</div>
<div id="pure-red-cell-aplasia" class="section level4">
<h4>Pure Red Cell Aplasia</h4>
<p>Considered whenever a patient receiving long term ESA therapy (more
than 8 weeks) develops all the following (2A):</p>
<ul>
<li>sudden decrease in Hb concentration at the rate of 5 to 10g/L per
week OR requirement of transfusions at the rate of approximately 1 to 2
per week</li>
<li>normal platelet and white cell counts,</li>
<li>absolute reticulocyte count less than 10,000/µl</li>
</ul>
<p>ESA therapy should be stopped in patients who develop ESA induced
PRCA.</p>
<p>Patients who remain transfusion dependent after withdrawing ESA
therapy should be treated with immunosuppressant medications guided by
the level of anti EPO antibodies</p>
<p>It was probably the rubber bungs on the old school <a
href="https://pubmed.ncbi.nlm.nih.gov/15824129/">EPREX syringes</a>
which were generating the antibodies, their removal from the market has
essentially fixed the issue</p>
</div>
</div>
</div>
<div id="hif-inhibitors" class="section level1">
<h1>HIF inhibitors</h1>
<p>Roxadustat is suss</p>
<p>A Roxadustat paper is being <a
href="https://retractionwatch.com/2021/05/11/clinical-trial-paper-that-made-anemia-drug-look-safer-than-it-is-will-be-retracted/">retracted</a></p>
<ul>
<li>compared roxadustat CV outcomes to EPO-alpha in non HD CKD - which
its not really indicated for due to increased CV endpoints</li>
<li>post-hoc changes to the stratification factors</li>
<li>Failed to sort out the issues on review so <a
href="https://www.kireports.org/article/S2468-0249(20)31851-9/fulltext">all
gone</a></li>
</ul>
<p>HIMALAYAS</p>
<p>Risks - Tumour progression - PAH - Increased cysts in ADPKD</p>
</div>



</div>
</div>

</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->

<script>
$(document).ready(function ()  {

    // temporarily add toc-ignore selector to headers for the consistency with Pandoc
    $('.unlisted.unnumbered').addClass('toc-ignore')

    // move toc-ignore selectors from section div to header
    $('div.section.toc-ignore')
        .removeClass('toc-ignore')
        .children('h1,h2,h3,h4,h5').addClass('toc-ignore');

    // establish options
    var options = {
      selectors: "h1,h2",
      theme: "bootstrap3",
      context: '.toc-content',
      hashGenerator: function (text) {
        return text.replace(/[.\\/?&!#<>]/g, '').replace(/\s/g, '_');
      },
      ignoreSelector: ".toc-ignore",
      scrollTo: 0
    };
    options.showAndHide = false;
    options.smoothScroll = true;

    // tocify
    var toc = $("#TOC").tocify(options).data("toc-tocify");
});
</script>

<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
